Abstract 362P
Background
The Lung Immune Prognostic Index (LIPI) is a clinical tool capable of predicting clinical outcomes in non-small cell lung cancer (NSCLC). We aimed to evaluate the prognostic impact of the baseline LIPI score and its association with blood immune-inflammatory profiles in patients (pts) with advanced NSCLC treated with immune checkpoint inhibitors (ICIs).
Methods
We collected baseline clinicopathological and circulating biomarker data from pts with advanced NSCLC treated with first-line chemoimmunotherapy (CT-IO). On blood samples, baseline LDH, derived Neutrophil-to-Lymphocyte ratio (dNLR) and their combinations in the LIPI score (good, intermediate, poor) as well as comprehensive immune cell phenotyping (flow-cytometry), and serum multiplex cytokine array were prospectively evaluated. LIPI was correlated to progression free survival (PFS) and overall survival (OS) and blood immune parameters.
Results
Among 111 pts treated with CT-IO, those with good LIPI (N=38,34%) showed significant longer median OS (26.55 months [mo] for good LIPI vs 11.32 mo for intermediate LIPI vs 6.45 mo for poor LIPI, p=0.007) and longer median PFS (10 mo for good LIPI vs 4.28 mo for poor LIPI, p=0.03). Regarding circulating biomarkers, pts with good LIPI showed significantly lower levels of interleukin (IL)-10 (p < 0.001), and IL-6 (p=0.02), higher CD3+ lymphocytes (p=0.008), mostly CD4+ subset expressing PD1 (p=0.01), Ki67 (p=0.02), perforin (p=0.04), and NKs (p=0.03) compared to pts with intermediate or poor LIPI. Furthermore, pts with good LIPI had a significantly better performance status and a lower rate of bone metastases at baseline.
Conclusions
Baseline LIPI score is a non-invasive clinical tool that predicts conveniently and reliably first-line CT-IO efficacy in advanced NSCLC and correlates with circulating cytokines and immune cell profiles, reflecting anti-tumour immune activity.
Funding
AIRC
Disclosure
All authors have declared no conflicts of interest.